Pfizer Eyes Protalix Biotherapeutics After Promising Clinical Trials

To read the full article, please choose one of the following options:

Two weeks after Israeli Protalix Biotherapeutics announced the success of phase III clinical trials for a pipeline treatment for Gaucher's disease, Pfizer has shown notable interest in the firm through a preliminary meeting. While speculation mounts over a possible buy-out, we note that Pfizer are more likely to take a cautious stance, particularly since a co-operative or co-licensing deal is a more attractive option. Teva is likely to show interest in Protalix as the company's chairman holds a 9.9% stake in the smaller biopharmaceutical firm. However, at this early stage, we believe that much depends on the strength of Protalix's